Navigation Links
China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*)
Date:1/26/2012

SICHUAN, China, Jan. 26, 2012 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that it has signed two new agreements for the sale of Gastrodia valued at 67.5 Million RMB or approximately $10.7 Million USD (Corrected*).  The agreements are with Chongqing Valley Pharm Corp and Sichuan Zhiyuanguanghe Pharm Corp and provide for a combined purchase total of 550 tons of Gastrodia from January 1, 2012 to December 31, 2012.

CHRI recently signed a 3 year exclusive agreement with a leading producer of Gastrodia in Pingwu, Sichuan. The quality of Gastrodia under this supply agreement is expected to meet the latest formal TCM pharmaceutical standard and gives CHRI continued leverage in the Traditional Chinese Medicine (TCM) marketplace in China, as the main controlling distributor and supplier of pharmaceutical grade Gastrodia (also known as Tianma).

"Demand is high for pharmaceutical grade Gastrodia and the company expects both our Gastrodia product revenues and bottom line will surpass last year.  We have started the new year with strong demand aided by our brand recognition and high quality GAP standards," stated Jiayin Wang, Chairman and CEO of CHRI.

Gastrodia is recognized as one of the higher value herbs in TCM.

"We have announced continuous record growth for 2011 and anticipate continued double-digit growth for Gastrodia product line in 2012.  We anticipate another record breaking year in our revenues and profits," says Weihai Liu, CFO of CHRI.

"In addition to great opportunities for Gastrodia, Dahurian Angelica (DAR) is successfully established as a franchise.   With our Dragonhead Enterprise status, which confirms CHRI as a quality-oriented government sanctioned enterprise, we are positioned  for a large scale global market penetration for CHRI's products," says Jiayin Wang.

(*) "An earlier version of this release erroneously reported the revenue from the agreements as $1.7 million US Dollars instead of $10.7 Million US Dollars and 67.5 RMB instead of 67.5 Million RMB."

About CHRI

China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of raw and pharmaceutical TCM products including Dahurian Angelica Root (DAR) and Rhizoma Gastrodiae and is only the provider of GAP quality DAR in the People's Republic of China under the registered Trademark Chuan Baizhi™. DAR, which is also known as "Bai Zhi" in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The Company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The Company was founded in 2001 and is based in Suining, Sichuan Province.

For more information, please visit http://chinahealthresource.com.

Certain statements in this document regarding financial matters, other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.


'/>"/>
SOURCE China Health Resource, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Health Resource Signs 3 Year Exclusive Agreement for Acquisition of Gastrodia Extending Very Successful Product Line Through 2015
2. China Health Resource Pharmaceutical Grade Gastrodia Product Line Expected to Contribute $8 Million in Revenue to 2011 Year End
3. BioChina International 2012
4. China Pharmaceutical Equipment Industry Report, 2011-2012
5. China Kanghui Holdings Renews High and New Technology Enterprises Status of Its PRC Operating Subsidiaries
6. Airway and Anesthesia Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
7. China Health Resource CEO Delivers Speech at 10th Year Anniversary Celebration
8. Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
9. China Kanghui Holdings Receives FDA Approvals for Hip and Knee Systems
10. China Kanghui Holdings to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Vivo Ventures Closes $375 Million 7th Fund to Invest in Healthcare in the U.S. and Greater China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Novavax, Inc., (Nasdaq: NVAX ) today announced that ... its RSV F protein recombinant nanoparticle vaccine candidate (RSV F ... in the journal Vaccine (the data ... conferences). The Company previously announced top line results ... RSV F Vaccine with the goal of protecting infants from ...
(Date:6/3/2017)...  Eli Lilly and Company (NYSE: ... Phase 3 MONARCH 2 study showed that abemaciclib, ... combination with fulvestrant, significantly improved progression-free survival (PFS) ... with hormone-receptor-positive (HR+), human epidermal growth factor receptor ... or progressed after endocrine therapy (median PFS, 16.4 ...
(Date:5/30/2017)... May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... Global Healthcare Conference on Tuesday, June 13, 2017, in ... , Hill-Rom,s president and chief executive officer, is scheduled to ... audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . A ... the live event through September 13, 2017. ...
Breaking Medicine Technology:
(Date:6/20/2017)... MA (PRWEB) , ... June 20, 2017 , ... Kenneth ... International AIDS Society (JIAS). , Dr. Mayer, who joined the JIAS Editorial Board ... is the founding Medical Research Director of Fenway Health and Co-Chair of ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Leading dental clinicians, ... imaging technology with the VATECH PaX-i and Anatomage systems. With advanced digital images and ... they can place dental implants precisely and restore oral health for those who are ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... Clinical Innovation Catalyst program focused on finding product improvements that could reduce ... in their throats when they need help breathing or to provide medication. Sometimes, ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... staffing agency, recently became re-accredited by the Joint Commission, which accredits ... Commission accreditation and certification is recognized nationwide as a symbol of quality that ...
(Date:6/20/2017)... ... 20, 2017 , ... The law firm of Momkus McCluskey Roberts LLC ... of the DuPage County Bar Association’s Board of Directors. Cassioppi officially took on the ... Drake in Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also ...
Breaking Medicine News(10 mins):